GURU.Markets stock price, segment price, and overall market index valuation
The company's share price OptiNose Inc.
OptiNose is a pharmaceutical company specializing in medications for sinus conditions. Its stock price reflects the success of commercializing its products, which utilize a unique drug delivery technology.
Share prices of companies in the market segment - Pharma other
OptiNose, Inc. is a pharmaceutical company that has developed a unique technology for delivering medications deep into the nasal cavity for the treatment of migraines and other conditions. We have classified it in the "Other Pharmaceuticals" category. The chart below shows how the market values companies with innovative drug delivery systems.
Broad Market Index - GURU.Markets
OptiNose, Inc. is a pharmaceutical company that has developed a unique technology for delivering medications deep into the nasal cavity for the treatment of migraines and other conditions. We've classified it in the "Other Pharmaceuticals" category. The chart below shows how the market values companies with innovative drug delivery systems.
Change in the price of a company, segment, and market as a whole per day
OPTN - Daily change in the company's share price OptiNose Inc.
OptiNose, Inc.'s daily stock price fluctuations reflect the volatility of the pharmaceutical sector. The metric is sensitive to sales of its nasal sprays and the success of its marketing strategy, serving as an indicator of commercial success.
Daily change in the price of a set of shares in a market segment - Pharma other
OptiNose is a pharmaceutical company that has developed a unique device for delivering drugs into the nasal cavity. Its success depends on the commercialization of this technology. The chart below shows the volatility in the pharmaceutical sector, which helps assess how the market is responding to OPTN's innovations.
Daily change in the price of a broad market stock, index - GURU.Markets
OptiNose is a pharmaceutical company that has developed a unique technology for nasal drug delivery. The company's shares are volatile and depend on the success of its product commercialization, contributing innovatively to the overall market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization OptiNose Inc.
OptiNose, Inc.'s year-over-year performance is a story about the commercialization of its unique drug delivery technology. Its 12-month market cap growth reflects sales of its XHANCE® nasal spray. Its valuation is a bet that its exhalation-delivery technology will find a niche in the market.
Annual dynamics of market capitalization of the market segment - Pharma other
OptiNose is a commercial pharmaceutical company specializing in ear, nose, and throat medications. This chart shows how its niche strategy, sales success of its key drug, and competitive environment influence its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
OptiNose, a pharmaceutical company that has developed a unique technology for nasal drug delivery, has a commercial product on the market. Its year-over-year market capitalization reflects sales growth and the ability to expand the application of its technology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization OptiNose Inc.
OptiNose is a commercial pharmaceutical company. Its monthly growth is directly dependent on the commercial success of its XHANCE nasal spray. Quarterly reports on prescription growth and revenue are key indicators.
Monthly dynamics of market capitalization of the market segment - Pharma other
OptiNose has developed a unique technology for delivering medications deep into the nasal cavity via exhalation. Their main product is designed to treat chronic rhinosinusitis. The graph below illustrates the overall dynamics in the pharmaceutical sector, where innovative delivery systems can create new value for patients.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of pharmaceutical companies with niche products can move on sales news and regulatory decisions. The chart below shows the general trends. Is OptiNose, Inc. living up to its story, where sales growth trumps overall market sentiment?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization OptiNose Inc.
The weekly performance of OptiNose, a pharmaceutical company, reflects niche markets. Its stock price is reflecting sales of its nasal polyp treatment, which uses a unique drug delivery technology.
Weekly dynamics of market capitalization of the market segment - Pharma other
OptiNose develops and markets nasal sprays using its unique exhalation technology. This chart compares its weekly performance with the pharmaceutical sector and helps us understand how its patented drug delivery system gives it a competitive advantage and impacts its valuation.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
OptiNose is a pharmaceutical company. Its success depends on the commercialization of its products. This chart will help you understand: does OptiNose stock live its own life, reacting to sales volumes and news, or does the overall dynamics of the pharmaceutical sector and the market determine its trend?
Market capitalization of the company, segment and market as a whole
OPTN - Market capitalization of the company OptiNose Inc.
OptiNose's market capitalization tells the story of a pharmaceutical company that has developed a unique technology for delivering drugs to the nasal cavity. The chart reflects the commercialization of its first product. Its dynamics reflect the market's assessment of its platform's potential for treating not only the common cold but also more serious conditions, such as migraines.
OPTN - Share of the company's market capitalization OptiNose Inc. within the market segment - Pharma other
OptiNose is a pharmaceutical company focused on treating ear, nose, and throat diseases. Its market share reflects the commercial success of its unique drug delivery technology. The chart illustrates how the market values its niche yet innovative business model.
Market capitalization of the market segment - Pharma other
OptiNose is a pharmaceutical company that has developed a unique technology for nasal drug delivery. The chart below shows the overall market capitalization of this sector. Its dynamics provide the backdrop against which OptiNose is attempting to commercialize its platform, offering new treatments for migraines and other conditions.
Market capitalization of all companies included in a broad market index - GURU.Markets
OptiNose is a pharmaceutical company specializing in the development of nasal-delivered drugs. Its capitalization is a bet on its unique delivery technology, which could improve drug efficacy. Its momentum exemplifies how innovation can extend not only to the molecule itself but also to the way it's administered.
Book value capitalization of the company, segment and market as a whole
OPTN - Book value capitalization of the company OptiNose Inc.
OptiNose's book value is derived from its equity and patents for its unique technology for delivering medications deep into the nasal cavity. This is a tangible, science-intensive foundation for more effective treatment of migraines and other conditions. How has this specialized pharmaceutical asset changed? The chart below shows its dynamics.
OPTN - Share of the company's book capitalization OptiNose Inc. within the market segment - Pharma other
OptiNose produces a device for delivering medications to the nasal cavity. The chart shows the proportion of its manufacturing and R&D assets, reflecting the scale of its unique technology, which improves the treatment of many diseases.
Market segment balance sheet capitalization - Pharma other
OptiNose, a pharmaceutical company, has a moderately capital-intensive business. This requires ownership of R&D and commercial infrastructure for its drugs. The BCap_Seg chart for the biotech sector shows that commercial success requires a substantial financial base.
Book value of all companies included in the broad market index - GURU.Markets
OptiNose's assets include its technology and commercial product, XHANCE, a device for deep sinus drug delivery for the treatment of chronic rhinosinusitis. Its balance sheet reflects its patents and commercial infrastructure. The chart below shows the pharmaceutical company's net worth.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - OptiNose Inc.
OptiNose develops unique devices for drug delivery to the nasal cavity. Its balance sheet is based on patents for these devices. Its market capitalization is a bet that its delivery method will be more effective than traditional ones. The chart shows how the market assesses the commercial potential of this innovative technology.
Market to book capitalization ratio in a market segment - Pharma other
OptiNose, Inc. has developed a unique technology for deep nasal drug delivery. Its market valuation on the chart reflects the commercial potential of its patented platform and the market success of its products, which is valued above the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
OptiNose, Inc. develops drug delivery systems where value is created through patents and unique technology. Its market capitalization reflects the potential of this technology. This chart compares how investors value niche medical innovations against broader market trends.
Debts of the company, segment and market as a whole
OPTN - Company debts OptiNose Inc.
OptiNose, a pharmaceutical company that has developed a unique technology for nasal drug delivery, is using debt to commercialize its products. This chart shows how the company is funding its sales and marketing efforts to convince doctors and patients of the benefits of its innovative treatment approach.
Market segment debts - Pharma other
OptiNose is a pharmaceutical company that has commercialized a device for nasal drug delivery. The product's market availability doesn't eliminate marketing and research costs. This chart shows how the company manages its debt, balancing sales revenue with expenses for promoting its unique technology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio OptiNose Inc.
OptiNose is a pharmaceutical company that has developed a unique technology for delivering drugs into the nasal cavity. This chart shows how the company uses debt to finance the marketing of its products and further research. It helps assess its financial stability and the risks associated with the commercialization of its technology.
Market segment debt to market segment book capitalization - Pharma other
OptiNose has developed a unique technology for delivering drugs deep into the nasal cavity (Exhalation Delivery System) for the treatment of chronic rhinosinusitis. The chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing how OptiNose is funding the commercialization of its niche product.
Debt to book value of all companies in the market
OptiNose, Inc. developed a unique technology for nasal drug delivery, which required investment in R&D and commercialization. This chart, showing the company's overall debt burden in the market, helps understand how the company manages its debt after launching a product and balances marketing expenses with the pursuit of profitability.
P/E of the company, segment and market as a whole
P/E - OptiNose Inc.
OptiNose is a pharmaceutical company that has developed a unique technology for nasal drug delivery. This chart shows how the market is evaluating its platform. The trend reflects the success of its commercial products and the potential for this technology to be applied to other drugs.
P/E of the market segment - Pharma other
This chart for pharmaceutical companies serves as a benchmark for OptiNose. It reflects how investors value the sector on average. Comparisons with this chart help understand how the market views OptiNose's unique nasal drug delivery technology and whether it believes in the commercial potential of its products, particularly for the treatment of chronic rhinosinusitis.
P/E of the market as a whole
OptiNose is a pharmaceutical company that has developed a unique device for delivering drugs into the nasal cavity. Its valuation depends on the commercial success of its products based on this technology. General market sentiment, reflected in this chart, has little impact on its business, which is determined by the specifics of its niche market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company OptiNose Inc.
For OptiNose, Inc., a pharmaceutical company with a unique nasal drug delivery technology, this chart shows market expectations for sales of its products. It reflects forecasts for growth in the number of patients using its devices to treat chronic rhinosinusitis and other conditions.
%20P%2FE%20OptiNose%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-OptiNose-Inc.&v=1772602313528 "Chart of the company's future (projected) P/E OptiNose Inc.")
Future (projected) P/E of the market segment - Pharma other
OptiNose is a pharmaceutical company specializing in the development and commercialization of products for the treatment of ear, nose, and throat (ENT) diseases. Its primary product is XHANCE, a nasal spray for the treatment of polyps. The chart shows industry forecasts. This helps assess how the market perceives the commercial success of XHANCE and the potential of the OptiNose technology platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772602313554 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
OptiNose, Inc. is a pharmaceutical company specializing in the development of drugs for the treatment of ear, nose, and throat diseases using its unique delivery system. Success depends on the commercialization of this technology. This graph of overall market sentiment influences the valuation of niche pharmaceutical companies with innovative products.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772602313559 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit OptiNose Inc.
OptiNose is a pharmaceutical company that has developed a unique technology for delivering medications into the nasal cavity. Its profits depend on sales of drugs using this technology. This chart shows how the company is trying to monetize its innovative delivery system and compete with traditional treatment methods.
Profit of companies in the market segment - Pharma other
OptiNose has developed and commercialized a unique intranasal drug delivery device that allows drugs to reach deep into the nasal cavity. This chart, which reflects pharmaceutical sector profitability, demonstrates how delivery innovations can improve the effectiveness of established medications. Their technology is used to treat chronic rhinosinusitis.
Overall market profit
OptiNose, Inc. has developed a unique technology for delivering medications into the nasal cavity, increasing their effectiveness in treating conditions such as chronic rhinosinusitis. The company's commercial success depends on the acceptance of this new technology by physicians and patients. Overall economic stability, as reflected in the graph, facilitates the implementation of innovative medical solutions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company OptiNose Inc.
OptiNose is a pharmaceutical company that has developed a unique technology for delivering medications deep into the nasal cavity via exhalation (Exhalation Delivery System). Its primary product is designed to treat chronic rhinosinusitis. This chart shows analysts' forecasts for sales growth and adoption of this innovative technology by doctors and patients.
%20profit%20of%20the%20company%20OptiNose%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-OptiNose-Inc.&v=1772602313706 "Graph of future (projected) profit of the company OptiNose Inc.")
Future (predicted) profit of companies in the market segment - Pharma other
OptiNose is a pharmaceutical company that has developed a unique technology for delivering drugs into the nasal cavity (Exhalation Delivery System). Its primary product is designed to treat chronic rhinosinusitis. Growth depends on the adoption of its technology. This chart for the pharmaceutical sector provides a general context for assessing the potential of new drug delivery systems.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772602313758 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
OptiNose develops and markets medications for the treatment of ear, nose, and throat conditions. Demand for its products depends on physician prescriptions and insurance coverage. The overall economic situation, reflected in this forecast, impacts patients' financial situation and their ability to afford brand-name medications.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772602313825 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - OptiNose Inc.
OptiNose is a pharmaceutical company that has developed a unique technology for delivering drugs to the nasal cavity. The chart shows how investors estimate the revenue from its commercial product. It reflects the potential of its platform to improve the treatment of various conditions, from chronic rhinosinusitis to migraines.
P/S market segment - Pharma other
OptiNose, Inc. has developed a unique nasal drug delivery technology that could improve the treatment of conditions such as chronic rhinosinusitis. The company's revenue depends on sales of products based on this technology. This chart shows the average valuation in the pharmaceutical industry, helping to understand how the market values OptiNose's innovative delivery system.
P/S of the market as a whole
OptiNose is a pharmaceutical company that has developed and markets a unique technology for delivering medications to the nasal cavity (Exhalation Delivery System). This chart, showing the average market revenue estimate, helps understand how investors value the company, whose value lies not only in the drugs themselves but also in the innovative delivery platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company OptiNose Inc.
OptiNose is a pharmaceutical company that has developed a unique technology for delivering drugs into the nasal cavity (Exhalation Delivery System). Its key product is a spray for treating nasal polyps. This chart shows how investors estimate the future sales of this product and the potential for its delivery technology to be applied to other drugs.
%20P%2FS%20OptiNose%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-OptiNose-Inc.&v=1772602314093 "The graph of the company's future (projected) P/S OptiNose Inc.")
Future (projected) P/S of the market segment - Pharma other
OptiNose, Inc. is a pharmaceutical company specializing in the development and commercialization of products for the treatment of ear, nose, and throat (ENT) diseases using its proprietary drug delivery technology. This chart shows the average estimated future sales in the pharmaceutical sector. It helps understand how the market values OptiNose's innovative products.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772602314096 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
OptiNose, Inc. has developed and commercialized an innovative device for delivering medications into the nasal cavity, increasing their effectiveness. The graph below shows how the market as a whole views revenue growth prospects. The company's technology has the potential to improve the treatment of a range of conditions, from chronic rhinosinusitis to migraines, setting new standards in ENT practice.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772602314158 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales OptiNose Inc.
This chart shows the sales of OptiNose, Inc., a pharmaceutical company whose key product is XHANCE, a device for delivering medications to the sinuses for the treatment of chronic rhinosinusitis. Revenue is generated from sales of this product. The trend reflects the number of prescriptions written and its market share.
Sales of companies in the market segment - Pharma other
OptiNose, Inc. is a pharmaceutical company specializing in the development of medications for the treatment of ear, nose, and throat (ENT) diseases using its unique nasal spray technology. This chart shows revenue in this segment. The company's technology allows for deeper drug delivery into the nasal cavity, increasing their effectiveness and creating a competitive advantage.
Overall market sales
OptiNose is a pharmaceutical company specializing in the development of medications for ear, nose, and throat diseases using its delivery technology. Its sales are dependent on physician prescriptions and insurance coverage. The overall economic situation, reflected in this chart, influences consumer spending on medications.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company OptiNose Inc.
OptiNose is a pharmaceutical company that has developed a unique technology for nasal drug delivery, enabling the treatment of conditions previously inaccessible to this approach. Future revenue depends on sales of its flagship product. The chart shows the forecast for this innovative technology.
%20sales%20of%20the%20company%20OptiNose%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-OptiNose-Inc.&v=1772602314203 "Schedule of future (projected) sales of the company OptiNose Inc.")
Future (projected) sales of companies in the market segment - Pharma other
OptiNose is a pharmaceutical company specializing in the development of drugs for the treatment of ear, nose, and throat (ENT) diseases using its unique nasal drug delivery technology. This graph shows the forecast for the entire pharmaceutical market, where innovative delivery methods like OptiNose's can improve the effectiveness of therapy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772602314223 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
OptiNose is a pharmaceutical company specializing in the development of treatments for ear, nose, and throat diseases using its unique drug delivery technology. This graph, reflecting overall consumer healthcare spending, influences the demand for prescription drugs and the willingness of insurers to cover them.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772602314242 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality OptiNose Inc.
OptiNose is a pharmaceutical company that has developed a unique technology for delivering medications to the nasal cavity. The company's profitability depends on successful sales of its products, particularly its nasal polyp treatment spray. This chart shows how the company monetizes its patented technology by offering new solutions for treating ENT conditions.
Market segment marginality - Pharma other
OptiNose is a pharmaceutical company that has developed a unique exhalation delivery system (Exhalation Delivery System) for the treatment of nasal and sinus conditions. Profitability depends on sales of their flagship product and physician acceptance of the new delivery method. This chart shows the commercial success of their innovative drug-device combination.
Market marginality as a whole
OptiNose is a pharmaceutical company that has developed a unique technology for delivering medications deep into the nasal cavity via exhalation. Their primary product is designed to treat chronic rhinosinusitis. This overall profitability curve is not important to them. Their success depends on marketing efforts and the acceptance of their unique delivery technology by doctors and patients.
Employees in the company, segment and market as a whole
Number of employees in the company OptiNose Inc.
OptiNose is a pharmaceutical company that has launched products using its unique nasal drug delivery technology. Its team includes a significant sales force. The growth in this chart reflects its commercial efforts to promote its products to physicians.
Share of the company's employees OptiNose Inc. within the market segment - Pharma other
OptiNose is a pharmaceutical company that has developed a unique technology for delivering medications deep into the nasal cavity. This chart reflects the scale of its commercial operations. A significant portion of its team consists of sales representatives who train physicians on how to use their innovative device to treat chronic rhinosinusitis.
Number of employees in the market segment - Pharma other
OptiNose, Inc. is a pharmaceutical company specializing in the development and commercialization of products for the treatment of ear, nose, and throat (ENT) diseases. This chart reflects employment trends in this highly specialized pharmaceutical niche. The growth in sales and marketing specialists is driven by the commercialization of the company's products and their promotion among otolaryngologists.
Number of employees in the market as a whole
OptiNose, Inc. has developed a technology for delivering medications to the nasal cavity. Demand for its products depends on physician prescriptions and insurance coverage. The stable employment seen in this graph means more patients have access to insurance that can cover the innovative, but more expensive, treatments offered by the company.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company OptiNose Inc. (OPTN)
OptiNose is a pharmaceutical company that has developed and markets a unique device (Xhance) for delivering medications into the nasal cavity (for the treatment of polyps). Their business involves not only R&D but also active sales to ENT specialists. The chart shows how the market values their niche product. The cost per employee reflects the balance between the value of the patent for the delivery device and the effectiveness of their sales team.
%20of%20the%20company%20OptiNose%20Inc.%20(OPTN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-OptiNose-Inc.-OPTN&v=1772602314393 "Chart of market capitalization per employee (in thousands of dollars) of the company OptiNose Inc. (OPTN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
OptiNose is a pharmaceutical company that has developed a unique technology for delivering medications deep into the nasal cavity. Its value lies not so much in the medications themselves, but in the patented device. This chart shows how the market values this innovative technology platform and its commercial potential.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772602314400 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
OptiNose, Inc. is a pharmaceutical company that has developed a unique technology for delivering drugs into the nasal cavity (Exhalation Delivery System). The chart shows the valuation of the company with a patented platform. It reflects how the team creates value by improving the effectiveness of existing drugs using its innovative device.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772602314449 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company OptiNose Inc. (OPTN)
OptiNose is a pharmaceutical company that markets Xhance, a drug for the treatment of chronic rhinosinusitis. Their selling point isn't the drug itself, but a unique delivery system (Exhalation Delivery System) that delivers the spray deep into the sinuses. This chart shows how successfully their sales team is monetizing this patented technology.
%20Chart%20OptiNose%20Inc.%20(OPTN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-OptiNose-Inc.-OPTN&v=1772602314529 "Company Profit Per Employee (in thousands of dollars) Chart OptiNose Inc. (OPTN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
OptiNose is a pharmaceutical company specializing in ear, nose, and throat disorders. Their flagship product is XHANCE spray. The company is in the commercialization phase. This metric reflects how successfully their sales team is promoting this niche drug to physicians.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772602314565 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
OptiNose (OPTN) is a biopharmaceutical company with an approved drug (Xhance) for the treatment of chronic rhinosinusitis, using its unique nasal delivery technology. It's a single-product company. This chart shows how successfully the commercial team is selling this drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772602314619 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee OptiNose Inc. (OPTN)
OptiNose is a pharmaceutical company that has developed a unique technology for delivering medications to the nasal cavity. This chart demonstrates the commercial success of its products. The increase in revenue per employee reflects the high demand for its nasal sprays and the effectiveness of its sales team in reaching physicians.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-OptiNose-Inc.-OPTN&v=1772602314838 "Sales chart per company employee OptiNose Inc. (OPTN)")
Sales per employee in the market segment - Pharma other
OptiNose is a pharmaceutical company that has achieved success thanks to its unique drug delivery technology (Exhalation Delivery System). Their flagship product, Xhance, treats nasal polyps. This chart shows how much revenue each Xhance employee generates, especially their sales team, compared to other pharmaceutical companies.
Sales per employee for the market as a whole
OptiNose (OPTN) is a pharmaceutical company that uses its Exhalation Delivery System (EDS) technology to deliver medications into the nasal cavity. The company has an approved product. This chart shows how efficiently the company's sales team generates revenue from sales of its main product to physicians (ENT specialists).
Short shares by company, segment and market as a whole
Shares shorted by company OptiNose Inc. (OPTN)
OptiNose is a pharmaceutical company that markets Xhance, a drug for the treatment of chronic rhinosinusitis, using its own nasal applicator. This chart shows bearish bets. Investors likely doubt the commercial launch is successful and that the device offers sufficient benefits.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-OptiNose-Inc.-OPTN&v=1772602314963 "Short Shares Chart for the Company OptiNose Inc. (OPTN)")
Shares shorted by market segment - Pharma other
OptiNose is a pharmaceutical company specializing in the development of treatments for ear, nose, and throat (ENT) diseases. Their key product utilizes a unique drug delivery technology. This chart measures the overall investor pessimism regarding the entire specialty pharmaceutical sector. It demonstrates the market's skepticism about the commercial success of niche drugs across the industry.
Shares shorted by the overall market
OptiNose (OPTN) is a clinical-stage biotech. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing OPTN won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator OptiNose Inc. (OPTN)
This chart for OptiNose is an indicator of commercial success in the pharmaceutical industry. The company sells Xhance (a spray) for the treatment of nasal polyps. "Overheating" (above 70) occurs due to strong sales growth reports or approval of a new indication (sinusitis). Slow physician adoption or insurance coverage issues lead to "oversold" conditions.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-OptiNose-Inc.-OPTN&v=1772602314984 "RSI 14 indicator chart for the company's stock OptiNose Inc. (OPTN)")
RSI 14 Market Segment - Pharma other
OptiNose (OPTN) isn't about the drug, it's about delivery. They've created a unique nasal spray (Xhance) that uses a patient's exhalation to deliver the drug deep into the sinuses. This chart tracks overall sentiment in the Pharmaceuticals sector. It helps investors understand whether OPTN's performance reflects their unique technology or whether the entire industry is overheated or oversold.
RSI 14 for the overall market
For OptiNose, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OPTN (OptiNose Inc.)
OptiNose (OPTN) is a pharmaceutical company known for its drug XHANCE for the treatment of chronic rhinosinusitis, which uses a proprietary nasal delivery technology. This chart shows the average 12-month forecast. It reflects analysts' expectations for XHANCE sales growth and its recent approval for broader use.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OPTN-OptiNose-Inc.&v=1772602315060 "A chart showing analyst consensus forecasts for the expected stock price. OPTN (OptiNose Inc.)")
The difference between the consensus estimate and the actual stock price OPTN (OptiNose Inc.)
OptiNose (OPTN) is all about "deep" delivery. Their unique "exhalation" nasal spray (Xhance) delivers medication *deep* into the sinuses to treat sinusitis. This chart measures the gap between the current price and the consensus target price. It shows the commercial potential analysts see in this unique delivery technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OPTN-OptiNose-Inc.&v=1772602315072 "A chart showing the difference between the consensus forecast and the actual stock price. OPTN (OptiNose Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma other
OptiNose is a specialized pharmaceutical company that developed a nasal expander (Xhance) for delivering drugs for chronic rhinosinusitis. This chart reflects analysts' overall expectations for the *entire* pharmaceutical sector. It shows whether experts believe in the commercial success of "niche" drug delivery methods.
Analysts' consensus forecast for the overall market share price
OptiNose (OPTN) – "delivery" to the brain. They developed an exhaled nasal spray (Xhance) that delivers medication deep into the sinuses, treating chronic sinusitis. This chart shows the general sentiment of experts. It reflects analysts' confidence in the stability of healthcare costs and the commercial success of niche drugs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index OptiNose Inc.
OptiNose is a nasal delivery system. Their gimmick isn't a drug, but a device (Exhalation Delivery System) that (they claim) delivers steroids (via exhalation) deeper into the sinuses (for polyps) than traditional sprays. This chart summarizes their rollout history. It reflects their (slow) sales and their (uphill) struggle for insurance reimbursement.
AKIMA Market Segment Index - Pharma other
OptiNose (OPTN) is another pharma company focused on ENT. Their key feature isn't a drug, but a device (Exhalation Delivery System) that delivers the drug (XHANCE) deep into the sinuses during exhalation. This chart compares their composite index to the sector, showing how their innovative delivery system outperforms the competition.
The AKIM Index for the overall market
OptiNose is a specialty pharmaceutical company that markets XHANCE, a nasal spray with a unique delivery system for the treatment of sinusitis. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this ENT drug's commercial performance compares to overall economic trends.
